JP2005512521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512521A5 JP2005512521A5 JP2003536444A JP2003536444A JP2005512521A5 JP 2005512521 A5 JP2005512521 A5 JP 2005512521A5 JP 2003536444 A JP2003536444 A JP 2003536444A JP 2003536444 A JP2003536444 A JP 2003536444A JP 2005512521 A5 JP2005512521 A5 JP 2005512521A5
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- protein
- alpha
- mutant
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/981,289 US7101974B2 (en) | 2000-03-02 | 2001-10-15 | TNF-αvariants |
| PCT/US2002/031277 WO2003033720A2 (en) | 2001-10-15 | 2002-09-30 | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005512521A JP2005512521A (ja) | 2005-05-12 |
| JP2005512521A5 true JP2005512521A5 (https=) | 2006-01-05 |
| JP4353802B2 JP4353802B2 (ja) | 2009-10-28 |
Family
ID=25528271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003536444A Expired - Lifetime JP4353802B2 (ja) | 2001-10-15 | 2002-09-30 | Ｔｎｆ−アルファ関連障害を処置するための、タンパク質をベースとするｔｎｆ−アルファ変異体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7101974B2 (https=) |
| EP (1) | EP1578988B1 (https=) |
| JP (1) | JP4353802B2 (https=) |
| CA (1) | CA2461245A1 (https=) |
| WO (1) | WO2003033720A2 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070172449A1 (en) * | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
| US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
| US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
| AU2003207464A1 (en) * | 2002-01-04 | 2003-07-24 | Xencor | Dominant negative proteins and methods thereof |
| US7381792B2 (en) * | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| EP2311867A1 (en) * | 2002-10-29 | 2011-04-20 | Anaphore, Inc. | Trimeric binding proteins for trimeric cytokines |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
| US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
| US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| EP1610825A2 (en) * | 2003-03-31 | 2006-01-04 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| EP1675871A2 (en) * | 2003-10-10 | 2006-07-05 | Xencor Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| TW200526780A (en) * | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| JP2010513245A (ja) * | 2006-12-14 | 2010-04-30 | アクトジェニックス・エヌブイ | 免疫調節を誘起するための結合分子の送達 |
| RU2529951C2 (ru) | 2007-12-26 | 2014-10-10 | Ксенкор, Инк. | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| US8722860B2 (en) | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US9445990B2 (en) | 2010-10-06 | 2016-09-20 | Medtronic, Inc. | TNF inhibitor formulation for use in implantable infusion devices |
| US9060978B2 (en) | 2011-01-24 | 2015-06-23 | Warsaw Orthopedic, Inc. | Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist |
| EP2718457A4 (en) * | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| WO2016029043A1 (en) | 2014-08-21 | 2016-02-25 | The General Hospital Corporation | Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same |
| EP3292140B1 (en) | 2015-05-05 | 2022-04-20 | Rubicon Biotechnology LLC | Cancer immunotherapeutic |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| US10468119B2 (en) | 2015-07-28 | 2019-11-05 | Yeda Research And Development Co. Ltd. | Stable proteins and methods for designing same |
| EP3329037B1 (en) * | 2015-07-28 | 2023-10-18 | Yeda Research and Development Co. Ltd. | Stable proteins and methods for designing same |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CN106800597B (zh) * | 2015-11-26 | 2021-07-16 | 上海佳文英莉生物技术有限公司 | 一种中和促细胞程序性坏死抗体的蛋白及其应用 |
| US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| MX385819B (es) | 2016-11-09 | 2025-03-18 | Philogen Spa | Inmunoconjugados mutantes de interleucina-2 y de factor de necrosis tumoral. |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| EP3580230B1 (en) | 2017-02-07 | 2026-04-22 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| US12091463B2 (en) | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| CN120590542A (zh) | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CN111909267B (zh) * | 2019-05-07 | 2022-03-25 | 北京天成新脉生物技术有限公司 | 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用 |
| WO2020257412A1 (en) | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| US12564620B2 (en) | 2021-09-15 | 2026-03-03 | Virginia Commonwealth University | Treatment of gulf war illness |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5288852A (en) | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| US4677064A (en) | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4894439A (en) | 1986-05-22 | 1990-01-16 | Cetus Corporation | N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes |
| CA1340998C (en) | 1986-02-04 | 2000-05-23 | Den'ichi Mizuno | Dnas and processes for their preparation, novel plasmids possessing them, novel polypeptides and processes for their preparation and novel anti-tumor agents comprising said polypeptides |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| DE3750056T2 (de) | 1986-06-20 | 1995-04-06 | Dainippon Pharmaceutical Co | Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| JPS6330426A (ja) | 1986-07-25 | 1988-02-09 | Mitsubishi Chem Ind Ltd | 自己免疫性疾患治療薬 |
| US5151349A (en) | 1986-12-04 | 1992-09-29 | Suntory Limited | Method for expressing polypeptide having anti-tumor activity |
| JPH07106158B2 (ja) | 1986-12-04 | 1995-11-15 | サントリー株式会社 | 抗腫瘍活性を有する新規ポリペプチドおよびその製造法 |
| DE3716513A1 (de) | 1987-05-16 | 1988-11-24 | Basf Ag | Proteine mit tnf-wirkung |
| IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| JPH0797997B2 (ja) | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
| DE68926679T2 (de) | 1988-09-22 | 1996-10-17 | Teijin Ltd | Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids |
| DE3841768A1 (de) | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
| DE3843534A1 (de) | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
| JP3203599B2 (ja) | 1989-10-24 | 2001-08-27 | カイロン コーポレイション | 感染性タンパク質デリバリーシステム |
| JP2685608B2 (ja) | 1989-12-08 | 1997-12-03 | 帝人株式会社 | 新規生理活性ポリペプチド |
| JPH03297388A (ja) | 1990-04-17 | 1991-12-27 | Ube Ind Ltd | 新規なｔｎｆ変異体、その製造法及びそれを有効成分とする抗腫瘍剤 |
| JPH0479880A (ja) | 1990-07-24 | 1992-03-13 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
| JPH04368398A (ja) | 1991-06-17 | 1992-12-21 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
| JP3157571B2 (ja) | 1990-09-21 | 2001-04-16 | 石原産業株式会社 | ポリペプチド |
| JPH05255393A (ja) | 1990-09-21 | 1993-10-05 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
| JPH04182497A (ja) | 1990-11-16 | 1992-06-30 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
| JPH04182498A (ja) | 1990-11-16 | 1992-06-30 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| US5160483A (en) | 1991-05-07 | 1992-11-03 | The University Of Tennessee Research Corporation | Fragment of TNF-α for promoting wound healing |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| JPH05271289A (ja) | 1992-03-17 | 1993-10-19 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
| WO1994018325A1 (en) | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
| KR970005042B1 (ko) * | 1993-02-09 | 1997-04-11 | 한일합성섬유공업 주식회사 | 종양괴사인자-알파 뮤테인 |
| CA2119089A1 (en) | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| US5606023A (en) | 1994-05-24 | 1997-02-25 | Thomas Jefferson University | Mutant tumor necrosis factor proteins |
| US5888814A (en) | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
| EP0974111B1 (en) | 1997-04-11 | 2003-01-08 | California Institute Of Technology | Apparatus and method for automated protein design |
| EP0980258A1 (en) | 1997-05-12 | 2000-02-23 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
| AU774334B2 (en) | 1998-10-16 | 2004-06-24 | Xencor | Protein design automation for protein libraries |
| AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
| US7056695B2 (en) * | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
| JP2003525612A (ja) * | 2000-03-02 | 2003-09-02 | ゼンコー | ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見 |
-
2001
- 2001-10-15 US US09/981,289 patent/US7101974B2/en not_active Expired - Fee Related
-
2002
- 2002-09-30 WO PCT/US2002/031277 patent/WO2003033720A2/en not_active Ceased
- 2002-09-30 CA CA002461245A patent/CA2461245A1/en not_active Abandoned
- 2002-09-30 JP JP2003536444A patent/JP4353802B2/ja not_active Expired - Lifetime
- 2002-09-30 EP EP02801645A patent/EP1578988B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512521A5 (https=) | ||
| JP4516719B2 (ja) | Ｔａｌｌ−１と結合するペプチド及び関連分子 | |
| TWI250988B (en) | Thrombopoietic compounds | |
| Zdanov | Structural features of the interleukin-10 family of cytokines | |
| WO2008000516B1 (en) | IMPROVED sgp130Fc DIMERS | |
| MX2012002428A (es) | Compuestos de union il-17 y usos medicos de los mismos. | |
| CN103172746A (zh) | 三聚体Fc融合蛋白及其用途 | |
| JP2002514418A5 (https=) | ||
| Lambris et al. | Third component of trout complement. cDNA cloning and conservation of functional sites. | |
| JP2016518367A (ja) | 虚血性損傷の治療及び予防用の組成物 | |
| KR20140135766A (ko) | 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법 | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| JPWO2018234492A5 (https=) | ||
| CA2407086A1 (en) | Integrin/adhesion antagonists | |
| US7820622B2 (en) | TNF antagonists | |
| MX2011005363A (es) | Peptidos para inhibicion del factor alfa de necrosis tumoral y usos de los mismos. | |
| Dong et al. | Human CD30: structural implications from epitope mapping and modeling studies | |
| CA2404429A1 (en) | Malaria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen | |
| JPWO2021229076A5 (https=) | ||
| AU2020270242B2 (en) | Anti-TNF-α humanized monoclonal antibody TCX060 having low immunogenicity and low ADCC/CDC function, and use thereof | |
| JPH05262788A (ja) | ペプチド類、その設計方法及び製造方法並びに受容体上の生理活性ペプチドの結合部位の決定方法 | |
| KR20250138100A (ko) | 응집체 성장 억제 기능을 갖는 생물학적 고분자 합성용 기재 및 이를 이용한 생물학적 고분자 합성 | |
| JPH01139597A (ja) | ペプチド | |
| JP2003528609A5 (https=) | ||
| KR20240133644A (ko) | 응집 방지 기능을 갖는 생물학적 고분자 합성용 기재 및 이를 이용한 생물학적 고분자 합성 방법 |